智通财经APP获悉，Organovo Holdings今日宣布，礼来(LLY.US)（Eli Lilly and Company）将收购该公司旗下的FXR项目及主打疗法FXR314。FXR314是一款潜在“best-in-class ...

Novartis has joined with Allergan in a bid to get ahead in the race to get a drug approved to treat the fatty liver disease, non-alcoholic steatohepatitis (NASH). The Swiss pharma said it is to ...

and is being studied in NASH with advanced fibrosis (scarring) and cirrhosis. LJN452 is Novartis’ most advanced of two Farnesoid X receptor (FXR) agonists. Other companies such as Intercept ...

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), are major health concerns. According to the American Liver Foundation, about 25% of adults ...

or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 ...